Find the Perfect Plan for Your Investment Journey
H
Latest price
52 Week Range
€2.89 - €11.95
Next Earnings Date
-
Next Earnings Date
-
Latest price
Market Cap | €177.72M |
EV | €155.38M |
Shares Outstanding | 28.00M |
Beta | 0.32 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | €12.50 |
P/E 2025E | - |
P/Revenue 2025E | 17.11x |
Revenue | 48.00% |
EPS | - |
Operating Cash Flow | 15.90% |
Free Cash Flow | -9.90% |
Revenue | 120.10% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | - |
Net Profit Margin 2025E | -183.49% |
ROE 2025E | - |
ROCE 2024 | -17.81% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
H
Hyloris Pharmaceuticals SA
HYL
Sector
Healthcare
Industry
Biotechnology
CEO
Van Rompay, Stijn
Employees
49
Website
hyloris.comIPO Date
2020-06-29
Headquarters
Boulevard Patience et Beaujonc N°3/1, Liège, Liège, 4000, Belgium
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved